- Home
- IMCC vs GTBP Comparison
IMCC vs GTBP Comparison
Compare IMCC & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCC | GTBP |
|---|---|---|
| Founded | 1980 | 1965 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 2.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMCC | GTBP |
|---|---|---|
| Price | $1.54 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 292.2K | ★ 1.2M |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,606,703.00 | N/A |
| Revenue This Year | $47.12 | N/A |
| Revenue Next Year | $12.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.92 | N/A |
| 52 Week Low | $0.93 | $0.54 |
| 52 Week High | $7.12 | $4.10 |
Technical Indicators
Market Signals| Indicator | IMCC | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 53.88 |
| Support Level | $1.41 | $0.63 |
| Resistance Level | $1.91 | $0.75 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 26.09 | 63.06 |
Price Performance
Historical ComparisonAbout IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.